

### **Amendment to the Claims**

#### **1-20. (Cancelled)**

**21. (New)** A preparation, which is obtained by a method comprising a step of coating a medicament-containing solid material with a coating solution comprising a water-insoluble polymer and a chitosan powder, wherein said polymer is selected from the group consisting of ethyl cellulose, Eudragit RS, and Eudragit NE30D, and the weight ratio of said chitosan powder to said water-insoluble polymer is in the range of about 1:4 to about 4:1.

**22. (New)** The preparation according to claim 21, which is further coated with an enteric polymer.

**23. (New)** The preparation according to claim 21, wherein the medicament-containing solid material is selected from the group consisting of a powder, a granule, a pellet, a capsule, and a tablet.

**24. (New)** The preparation according to claim 21, wherein the medicament-containing solid material is selected from the group consisting of a pellet, a capsule, and a tablet.

**25. (New)** The preparation according to claim 22, wherein the medicament-containing solid material is selected from the group consisting of a powder, a granule, a pellet, a capsule, and a tablet.

**26. (New)** The preparation according to claim 22, wherein the medicament-containing solid material is selected from the group consisting of a pellet, a capsule, and a tablet.

**27. (New)** The preparation according to claim 21, wherein the water-insoluble polymer is Eudragit RS.

**28. (New)** The preparation according to claim 22, wherein the water-insoluble polymer is Eudragit RS.

**29. (New)** A process for producing the preparation of claim 21, which comprises a step of coating a medicament-containing solid material with a coating solution comprising a water-insoluble polymer and a chitosan powder, wherein said polymer is selected from the group consisting of ethyl cellulose, Eudragit RS, and Eudragit NE30D.

**30. (New)** The process for producing the preparation according to claim 29, which comprises a step of coating the preparation of claim 29 with an enteric polymer.

**31. (New)** The preparation of claim 21, wherein said preparation passes through a stomach and small intestine, and the medicament is released at an accelerated rate in a large intestine relative to a rate of release in the stomach and small intestine.

**32. (New)** The preparation of claim 22, wherein said preparation possesses the property that said preparation passes through a stomach, and the medicament therein is not released in the stomach but is released in the large intestine without lag time.

**33. (New)** A preparation comprising a medicament-containing solid material coated by a water-insoluble polymer containing a chitosan powder dispersed in said polymer, wherein said polymer is selected from the group consisting of ethyl cellulose, Eudragit RS, and Eudragit NE30D, and the weight ratio of said polymer and said chitosan powder is from 4:1 to 1:4.

**34. (New)** The preparation of claim 33, which is further coated with an enteric polymer.

**35. (New)** The preparation according to claim 33, wherein the medicament-containing solid material is selected from the group consisting of a powder, a granule, a pellet, a capsule, and a tablet.

**36. (New)** The preparation according to claim 34, wherein the medicament-containing solid material is selected from the group consisting of a powder, a granule, a pellet, a capsule, and a tablet.

**37. (New)** The preparation according to claim 33, wherein the medicament-containing solid material is selected from the group consisting of a pellet, a capsule, and a tablet.

**38. (New)** The preparation according to claim 34, wherein the medicament-containing solid material is selected from the group consisting of a pellet, a capsule, and a tablet.

**39. (New)** The preparation according to claim 33, wherein the water-insoluble polymer is Eudragit RS.

**40. (New)** The preparation according to claim 34, wherein the water-insoluble polymer is Eudragit RS.